EGRX Eagle Pharmaceuticals Inc.

+0.99  (+2%)
Previous Close 45.24
Open 45.23
Price To Book 3.31
Market Cap 642597000
Shares 13,900,000
Volume 341,544
Short Ratio
Av. Daily Volume 193,960

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released October 30, 2018 did not meet primary endpoints.
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Malignant hyperthermia - cancer
Phase 2 trial ongoing.
MDMA/meth intoxication
Phase 3 completion of enrollment announced August 30, 2018.
Exertional heat stroke (EHS)

Latest News

  1. Is Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) ROE Of 15% Impressive?
  2. Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
  3. Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
  4. Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline
  5. Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
  6. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  7. Does Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) CEO Pay Matter?
  8. Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference
  9. Hedge Funds Are Selling Eagle Pharmaceuticals Inc (EGRX)
  10. Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results
  11. Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)
  12. Investors Are Undervaluing Eagle Pharmaceuticals Inc (NASDAQ:EGRX) By 28.8%
  13. Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
  14. Moving Average Crossover Alert: Eagle Pharmaceuticals (EGRX)